<DOC>
	<DOCNO>NCT02832999</DOCNO>
	<brief_summary>This single blind randomise controlled clinical trial uncontrolled type 2 Diabetes mellitus patient oral glucose lower agent , naive incretinomimetic . Participants randomise two Arms : arm 1 receive Liraglutide 1,2 mg/day arm 2 Vildagliptine 100mg/day 14 day . The two arm compare 14-day change insulin secretion insulin sensitivity .</brief_summary>
	<brief_title>Short Term Effect Liraglutide Versus Vildagliptine Insulin Secretion Insulin Sensitivity Type 2 Diabetes</brief_title>
	<detailed_description>Incretinomimetics include exogenous Glucagon-Like Peptide analog ( GLP1a ) Liraglutide , inhibitor Dipeptidyl peptidase IV ( DPP4i ) prolong half-life endogenous GLP1 Vildagliptin . It remain unclear two strategy ( exogenous GLP1 prolong half-life endogenous GLP1 ) good short term effect insulin sensitivity insulin secretion people live type 2 diabetes . This study aim investigate short-term metabolic effect GLP-1 analog Liraglutide versus DPP4i Vildagliptin . It randomize , control , single-blinded clinical trial . Study population consist uncontrolled type 2 diabetes mellitus patient ( HbA1c≥7 % ) mono bi oral anti-diabetic therapy , naïve incretinomimetic treatment . Participants randomize 2 arm . The intervention arm 1 consist add-on subcutaneous Liraglutide 0.6mg/day 1 week increase 1.2mg second week . In second arm , consist oral Vildagliptine 100mg daily two week . The primary outcome variation euglycaemic hyperinsulinaemic clamp-derived insulin sensitivity randomization day intervention , secondary outcome include 14-day change insulin secretion mixed meal tolarance test , body weight body composition , indirect calorimetry measure rest energy expenditure . Changes baseline 14 day serum creatinine alanine amino transferase , C-reactive protein lipid profile also record .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes mellitus know least one year Uncontrolled glycaemic profile HbA1c ≥ 7 % oral antidiabetic mono bitherapy Naïve incretinomimetic treatment Informed consent Change antidiabetic treatment le 3 month prior inclusion Pancreatitis Alanine amino transferase &gt; 3 time normal value Pregnant breastfeed woman Estimated glomerular filtration rate &lt; 60ml/min Infection less 10 day prior inclusion study Acute complication diabetes Total haemoglobin &lt; 11g/dL woman &lt; 13g/dL men Withdrawal consent</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>GLP-1</keyword>
	<keyword>Insulin secretion</keyword>
	<keyword>insulin sensitivity</keyword>
	<keyword>Africa</keyword>
	<keyword>Liraglutide</keyword>
	<keyword>Vildaglipin</keyword>
</DOC>